Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service DBS & VNS cases in Kansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (103 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 227 | 20% |
| 2020 | 2 | 226 | 23% |
| 2021 | 2 | 232 | 28% |
| 2022 | 3 | 132 | 31% |
| 2023 | 3 | 154 | 34% |
| 2024 | 3 | 294 | 36% |
| 2025 from claims | – | 395 319–464 | 36% |
| 2026 forecast | – | 426 333–535 | 36% |
| 2027 forecast | – | 459 340–606 | 36% |
| 2028 forecast | – | 494 350–682 | 37% |
| 2029 forecast | – | 532 362–763 | 37% |
| 2030 forecast | – | 574 376–851 | 37% |
Deep brain and vagus nerve stimulator implants. Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Kansas; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 34% inpatient hospital, 66% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 9 | 430−6.8%/yr | −6.8%/yr | 0.4 | 0% | 580 in 2030+5.2%/yr |
| Minnesota | 3 | 324−2.1%/yr | −2.1%/yr | 0.7 | 0% | 460 in 2030+6.1%/yr |
| Illinois | 4 | 294−8.4%/yr | −8.4%/yr | 0.2 | 0% | 330 in 2030+2.2%/yr |
| Missouri | 3 | 276−9.1%/yr | −9.1%/yr | 0.4 | 0% | 290 in 2030+0.5%/yr |
| Michigan | 2 | 246−8.8%/yr | −8.8%/yr | 0.3 | 0% | 130 in 2030−10%/yr |
| Indiana | 2 | 163−10%/yr | −10%/yr | 0.2 | 0% | 320 in 2030+12%/yr |
| Wisconsin | 3 | 158−3.1%/yr | −3.1%/yr | 0.3 | 0% | 140 in 2030−2.5%/yr |
| Iowa | 1 | 123−7.4%/yr | −7.4%/yr | 0.3 | 0% | 200 in 2030+8.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 8 | 152+1.4%/yr | +1.4%/yr | 0.40.9× | 0% | 110 in 2030−5.6%/yr |
| Aneurysm & intracranial embolization | 5 | 146+15%/yr | +15%/yr | 0.40.8× | 0% | 210 in 2030+6.6%/yr |
DBS & VNS in every state, and its device makers · Every procedure market in Kansas · Every state · Compare with Ohio
Livanova leads with 58% of company spending on these surgeons in 2025, +17 pts on 2024.
In 2025, 6 companies reported engagement with Kansas’s surgeons worth $52K in consulting, speaking, meals and travel tied to these products, about $17K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.